BioSpace News Archive

We are seeing the road maps being rolled out, province by province, on how to re-open the economy post COVID-19 – and we all know that there is a lot riding on our country and economy emerging from this crisis with strength and durability.

Strengthened financial profile provides additional resources to execute Covetrus’ strategic growth objectives while navigating COVID-19 pandemic

- FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), today announced that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator. The Therapeutics Accelerator is an initiative launched by the Bill & Meli

The company manufactures 99% of its medications in the United States, allowing it to reliably and quickly supply high-quality, life-saving treatments to those in need.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has received a No Objection Letter from Health Canada to proceed with a NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory au

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at: https://corporate.qiagen.com/investor-relations/financial-reports/other-reports QIAGEN N.V. further announc

Data presented on repurposing the existing, broad-spectrum antiviral agent using Thin Film Freezing and other techniques to enhance its effect for COVID-19 therapy

Accretive Acquisition Adds Profitable Award-Winning Dr. Denese Skin Care & Anti-Aging Lines, Which Generated Approximately $18 Million in Total Sales in 2019 and Over $500M in Sales on QVC Over the Last 17 Years [30-April-2020] SOUTH EASTON, Massachusetts , April 30, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader i

Pluristem Therapeutics Inc. provided a summary of an Investor & Analyst Call conducted on April 30, 2020, in conjunction with the European Investment Bank and kENUP Foundation.

MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone® platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria).